|
|
Debanjan Chakroborty, Uttio Roy Chowdhury, Chandrani Sarkar, Rathindranath Baral, Partha Sarathi Dasgupta, Sujit Basu
J Clin Invest. 2008;
118(4):1380
doi:10.1172/JCI33125
Abstract |
Full text
| PDF
| Supplemental material

M
obilization of endothelial progenitor cells (EPCs) from the bone marrow and their subsequent participation in neovessel formation are implicated in tumor growth and neovascularization. As the neurotransmitter dopamine (DA) modulates adult endothelial cell function, we hypothesized that DA might have a regulatory role in mobilization of EPCs from the bone marrow niche. We show that there was a significant decrease in bone marrow DA content and an increase in EPC mobilization in tumor-bearing mice associated with tumor neovascularization. DA treatment of tumor-bearing mice inhibited EPC mobilization and tumor growth through its D2 receptors, as DA treatment failed to inhibit EPC mobilization in tumor-bearing mice treated with a specific DA D2 receptor antagonist and in tumor-bearing mice lacking the D2 receptor. In addition, we found that DA, through D2 receptors, exerted its inhibitory effect on EPC mobilization through suppression of VEGFA-induced ERK1/ERK2 phosphorylation and MMP-9 synthesis. These findings reveal a new link between DA and EPC mobilization and suggest a novel use for DA and D2 agents in the treatment of cancer and other diseases involving neovessel formation.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(16)
| Title and authors |
Publication |
Year |
Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia
Raul Gómez, Antonio Abad, Francisco Delgado, Silvia Tamarit, Carlos Simón, Antonio Pellicer
|
Fertility and Sterility
|
2011 |
The neuronal influence on tumor progression
Mario Mancino, Elisabet Ametller, Pedro Gascón, Vanessa Almendro
|
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
|
2011 |
Neurotransmitters, more than meets the eye — Neurotransmitters and their perspectives in cancer development and therapy
Zhi Jie Li, Chi Hin Cho
|
European Journal of Pharmacology
|
2011 |
Increased levels of endothelial progenitor cells in Parkinson’s disease
Cavanna Ferruccio, Barichella Michela, Cassani Erica, Pezzoli Gianni
|
Parkinsonism & Related Disorders
|
2011 |
The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis
F. Delgado-Rosas, R. Gomez, H. Ferrero, F. Gaytan, J. Garcia-Velasco, C. Simon, A. Pellicer
|
Reproduction
|
2011 |
Impact of stress on cancer metastasis
Myrthala Moreno-Smith, Susan K Lutgendorf, Anil K Sood
|
Future Oncology
|
2010 |
Sympathetic Neurotransmitters and Tumor Angiogenesis—Link between Stress and Cancer Progression
Jason Tilan, Joanna Kitlinska
|
Journal of Oncology
|
2010 |
Resident Vascular Progenitor Cells—Diverse Origins, Phenotype, and Function
Peter J. Psaltis, Adriana Harbuzariu, Sinny Delacroix, Eric W. Holroyd, Robert D. Simari
|
J. of Cardiovasc. Trans. Res.
|
2010 |
The immunoregulatory role of dopamine: An update
Chandrani Sarkar, Biswarup Basu, Debanjan Chakroborty, Partha Sarthi Dasgupta, Sujit Basu
|
Brain, Behavior, and Immunity
|
2010 |
The particular relationship between Parkinson’s disease and malignancy: a focus on skin cancers
Rivka Inzelberg, Simon D. Israeli-Korn
|
J Neural Transm
|
2009 |
|